Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Chordia Therapeutics Inc

190A:TYO

Chordia Therapeutics Inc

Actions
  • Price (JPY)372.00
  • Today's Change-39.00 / -9.49%
  • Shares traded962.30k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 24 2024 03:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chordia Therapeutics Inc is a Japan-based drug discovery venture company mainly engaged in the research and development of novel anticancer drugs for commercialization. The Company's main business is the research and development of small molecule breakthrough drugs (first-in-class) with novel actions in the field of oncology, where there is a high unmet medical need. The Company concentrates on management and research operations (exploratory, preclinical, and clinical research), particularly in the discovery, evaluation, optimization, and clinical testing of candidate compounds, and outsources basic research, active pharmaceutical ingredient and drug product manufacturing, distribution, and sales to its various external partners to advance its business.

  • Revenue in JPY (TTM)--
  • Net income in JPY--
  • Incorporated2017
  • Employees21.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Frontage Holdings Corp37.44bn878.25m23.32bn1.66k26.960.48113.730.62290.0230.0230.98951.290.470156.234.181,152,014.001.064.461.305.2828.5634.002.269.921.252.190.3110.003.7925.61-58.00-0.782640.43--
Healios KK522.00m-5.39bn23.34bn64.00--7.19--44.72-68.16-68.166.5636.000.0321--1.618,156,250.00-33.11-23.55-49.17-28.5285.06---1,030.65-6,580.16---1.490.7469--34.44--26.04---22.00--
Jacobio Pharmaceuticals Group Co Ltd472.39m-7.37bn24.65bn298.00--1.34--52.17-0.5142-0.51420.03291.260.016--2.4184,951.02-24.89-45.76-28.66-49.303.45---1,560.88-372.22----0.1794---33.66--3.43--19.18--
Pharma Foods International Co., Ltd.62.15bn3.21bn25.79bn670.007.822.156.270.415113.47113.472,185.12412.691.712.1014.00--8.818.6325.3822.0678.4580.645.164.130.887581.160.593226.28-9.3742.624.0245.0128.23--
Immunotech Biopharm Ltd0.00-6.30bn27.00bn211.00--16.34-----0.6627-0.66270.000.17380.00----0.00-35.21-37.42-55.75-45.48--------0.3638-2.440.6119-------5.25---8.46--
Chordia Therapeutics Inc-100.00bn-100.00bn27.77bn21.00--6.98----------58.88----------------------------0.00------112.55------
TOT Biopharm International Co Ltd19.83bn182.66m28.55bn551.00146.721.9422.071.440.01360.01361.481.030.68992.446.351,947,891.000.6356-20.010.8392-25.2172.0274.740.9212-68.531.632.980.3465--76.5481.8824.36--21.04--
Race Oncology Ltd81.56m-1.35bn28.88bn----16.09--354.12-0.0839-0.08390.00510.10750.0355--0.9201---58.97-46.49-63.04-48.68-----1,659.82-2,995.74----0.00--40.68116.86-39.26------
Data as of Sep 24 2024. Currency figures normalised to Chordia Therapeutics Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.